Sun Pharmaceutical Industries announced its financial results for Q2FY26, showcasing substantial growth. Sales reached Rs. 144,052 million, an increase of 8.6% year-over-year. Net profit also saw a rise to Rs. 31,180 million, up by 2.6% year-over-year. The company highlighted strong performance in India and emerging markets, with Innovative Medicines contributing significantly to overall sales.
Financial Performance Highlights
Sun Pharma reported sales of Rs. 144,052 million for Q2FY26, reflecting an 8.6% growth. The net profit for the quarter stood at Rs. 31,180 million, marking a 2.6% increase. This performance underscores the company’s continued growth trajectory in a competitive market.
Segmental Performance
The company’s Innovative Medicines generated sales of US$ 333 million, which is a 16.4% increase, and accounted for 20.2% of total sales. This demonstrates the increasing significance of the company’s innovative portfolio. EBITDA was reported at Rs. 45,271 million, with a margin of 31.3%.
Regional Sales
India’s formulation sales were Rs. 47,348 million, showing a growth of 11% and contributing to 32.9% of the company’s total consolidated sales. Emerging markets recorded sales of US$ 325 million, with an increase of 10.9%.
R&D and Pipeline
Sun Pharma’s investment in R&D stood at Rs. 7,827 million, representing 5.4% of the sales. The company’s innovative R&D pipeline includes six novel entities currently in the clinical stage.
New Product Launches and Market Position
Sun Pharma maintains its position as India’s leading pharmaceutical company, holding a market share of 8.3%. During the quarter, the company launched 9 new products and has launched a total of 15 products to date.
Source: BSE
